Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Accuray Inc. (ARAY) Reports First U.S. Center Treats Patient with New TomoHDA System

Radiation oncology company Accuray today announced that the Tulsa Cancer Institute in Oklahoma is the first U.S. center to treat a cancer patient with its TomoHDA System. This product is the latest and most advanced innovation in the Tomo Therapy product line designed to treat the full range of cancer patients. Earlier this month, the System was installed at a center in France where the first European patient was treated with the device.

Among the TomoHDA System’s numerous benefits are streamlined daily 3D CT image guidance for accurate treatment delivery, faster treatment times, and the ability to create treatment plans that specifically target the cancer while sparing the surrounding healthy tissue. The TomoHDA now only allows cancer treatment centers to treat more patients daily, but also to maintain the patient’s quality of life as much as possible.

Daron Street M.D. of the Tulsa Cancer Institute said, “The flexibility of the TomoHDA System allows our physicians to not only treat common cancers but also tackle more complicated cancers in the most efficient, accurate way possible.” This should offer their patients the opportunity for the best possible clinical outcomes.

Accuray is a radiation oncology company that develops, manufactures, and sells innovative treatment solutions that set the standard of care in helping patients live longer, healthier lives. The company’s leading edge technologies deliver the full range of radiation therapy and radiosurgery treatments.

For additional information about Accuray, visit www.accuray.com

Let us hear your thoughts below:

This entry was posted in Small Cap News. Bookmark the permalink.

Comments are closed.